Massively Parallel Sequencing—Shaping the Future of Forensic DNA Casework

November 11, 2016

Hear from key opinion leaders in the field of forensic genomics about how massively parallel sequencing (MPS), also known as next-generation sequencing (NGS), is providing a new level of information from DNA samples. Information that can deconvolute mixed samples and provide a better picture of an individual’s physical appearance or ancestry. Information that could really swing a case.

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.

Subscribe to the Illumina video channel 

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos

Share this article on